Drug patents …
… from Kazakhstan to Kalamazoo
Anticipate generic drug launch
Manage your formulary budget
Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Find generic entry opportunities
Proactively manage your pharmacy inventory
Flat-rate pricing for predictable budgeting
Short-term plans for project- or client-based billing
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
|Title:||Muscle morphogenic protein and use thereof|
|Abstract:||A myogenic protein isolate from mammalian bone is provided that stimulates lineage commitment and differentiation of stem cells in vitro and in vivo. The protein isolate is characterized by its ability to cause muscle stem cell differentiation without excessive proliferation of connective tissue proximal to the delivery site. Treated muscle stem cells differentiate into myotubes and multinucleated structures with minimal formation of scar tissue, resulting in functional muscle tissue restoration in vivo, and therefore useful in the treatment of a number of disorders and injuries. The protein isolate is preferably administered by implanting a bioerodible polymer matrix, preferably a surface erodible polymer such as a polyanhydride or a polyorthoester, interspersed with the protein isolate near the site of muscle injury or degeneration, but can be administered directly to cells cultured in vitro.|
|Inventor(s):||Lucas; Paul A. (Macon, GA), Young; Henry E. (Macon, GA), Laurenchin; Cato T. (Somerville, MA)|
|Assignee:||Massachusetts Institute of Technology (Cambridge, MA)|
|Filing Date:||Feb 11, 1992|
|Claims:||1. A protein isolate comprising one or more water soluble proteins isolated from mammalian bone, wherein the protein isolate selectively stimulates stem cell myogenic lineage commitment and differentiation into myotubes and multinucleated structures in vitro and in vivo, contains proteins having molecular weights between 50,000 and 200,000 daltons, does not bind to DEAE in urea at pH 6.0, and binds to a cation exchange column at pH 6.0. |
2. The protein isolate of claim 1 wherein the protein isolate selectively stimulates myogenic stem cell differentiation into functional muscle tissue in vivo.
3. A method of inducing myogenesis n undifferentiated stem cells in culture or in a patient in need of treatment thereof comprising administering a therapeutically effective amount of between approximately 1 ng and 10 mg per kilogram of stem cells or body weight of a water soluble protein isolate extracted from mammalian bone to the stem cells to induce myogenic lineage commitment and differentiation into myotubes and multinucleated structures, wherein the protein isolate contains proteins having molecular weights between 50,000 and 200,000 daltons, does not blind to DEAE in urea at pH 6.0, and binds to a cation exchange column at pH 6.0.
4. The method of claim 3 wherein the protein isolate is administered to a wound in an amount effective to induce muscle repair.
5. The method of claim 3 wherein the administering step is performed by implanting in the patient in need thereof the protein isolate incorporated into a delivery vehicle that provides controlled release of the protein isolate at a site where myogenic stem cell differentiation is desired.
6. The method of claim 3 wherein the protein isolate is administered to the stem cells in culture or in the patient in need thereof in combination with a therapeutically effective amount of a compound selected from the group consisting of inducers of cell proliferation, antibiotics, and antiinflammatories.
7. The method of claim 2 wherein the patient to be treated has a disorder selected from the group consisting of muscular dystrophy, myasthenia gravis, multiple sclerosis, nerve block injuries, muscle atrophy, embryonic failure of myotomes to migrate, rhabdomyosarcoma, aneurysms, hemorrhage, ptosis, muscle tears, and muscle damaged by infarction.
8. The method of claim 5 wherein the delivery vehicle is a polymeric matrix.
9. The method of claim 8 wherein the polymeric matrix is selected from the group consisting of biocompatible bioerodible and non-erodible polymers.
10. The method of claim 9 wherein the bioerodible polymer is selected from the group consisting of surface eroding polymers and bulk eroding polymers.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.